Clene (CLNN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
The annual meeting is scheduled for May 21, 2026, with voting available online, by phone, mail, or in person, and only shareholders of record as of March 25, 2026, are eligible to vote.
Four main proposals are up for vote: election of three Class III directors, ratification of Deloitte as auditor, advisory approval of executive compensation, and an amendment to increase shares in the 2020 Stock Plan.
The board recommends voting in favor of all proposals and provides detailed instructions for proxy voting and revocation.
Voting matters and shareholder proposals
Shareholders will vote on electing three Class III directors for terms ending in 2029, ratifying Deloitte as auditor for 2026, approving executive compensation on an advisory basis, and amending the 2020 Stock Plan to add 1,000,000 shares.
The board recommends voting “FOR” all proposals; directors are elected by plurality, while other proposals require a majority of votes cast.
Shareholder proposals and director nominations for the 2027 meeting must be submitted between January 21 and February 20, 2027.
Board of directors and corporate governance
The board consists of nine directors divided into three classes with staggered three-year terms; a majority are independent.
Committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
The board emphasizes diversity, ethical conduct, and strong governance, with a code of conduct and policies for conflicts of interest.
Directors are encouraged to attend all meetings and participate in continuing education.
Latest events from Clene
- Key votes include director elections, auditor ratification, and stock plan share increase.CLNN
Proxy filing10 Apr 2026 - Net loss narrowed in 2025, with strong financing and positive ALS biomarker data supporting NDA plans.CLNN
Q4 202512 Mar 2026 - Strong biomarker and survival data for ALS therapy positions company for NDA filing and 2027 launch.CLNN
Emerging Growth Virtual Conference25 Feb 2026 - FDA to review ALS therapy data this quarter; NDA filing and commercialization targeted for 2025.CLNN
Emerging Growth Conference 8921 Jan 2026 - Accelerated approval for ALS is being pursued with robust neurofilament and survival data.CLNN
37th Annual ROTH Conference26 Dec 2025 - Registering 2.35M shares for resale as clinical-stage neurology biotech faces funding risks.CLNN
Registration Filing16 Dec 2025 - Registering shares for resale after note conversion; no proceeds to company; urgent funding needs.CLNN
Registration Filing16 Dec 2025 - Biotech aims to raise $160M for neurodegenerative drug trials amid urgent funding needs.CLNN
Registration Filing16 Dec 2025 - Registering shares for resale amid urgent funding needs and advancing neurodegenerative drug trials.CLNN
Registration Filing16 Dec 2025